Abstract |
High-density lipoprotein (HDL) is a key regulator of lipid homeostasis through its native roles like reverse cholesterol transport. The reconstitution of this natural nanoparticle (NP) has become a nexus between nanomedicine and multi-disease therapies, for which a major portion of HDL functionality is attributed to its primary scaffolding protein, apolipoprotein A1 (apoA1). ApoA1-mimetic peptides were formulated as cost-effective alternatives to apoA1-based therapies; reverse-4F (r4F) is one such peptide used as part of a nanoparticle platform. While similarities between r4F- and apoA1-based HDL-mimetic nanoparticles have been identified, key functional differences native to HDL have remained undetected. In the present study, we executed a multidisciplinary approach to uncover these differences by exploring the form, function, and medical applicability of engineered HDL-mimetic NPs (eHNPs) made from r4F (eHNP-r4F) and from apoA1 (eHNP-A1). Comparative analyses of the eHNPs through computational molecular dynamics (MD), advanced microfluidic NP synthesis and screening technologies, and in vivo animal model studies extracted distinguishable eHNP characteristics: the eHNPs share identical structural and compositional characteristics with distinct differences in NP stability and organization; eHNP-A1 could more significantly stimulate anti-inflammatory responses characteristic of the scavenger receptor class B type 1 (SR-B1) mediated pathways; and eHNP-A1 could outperform eHNP-r4F in the delivery of a model hydrophobic drug to an in vivo tumor. The biomimetic microfluidic technologies and MD simulations uniquely enabled our comparative analysis through which we determined that while eHNP-r4F is a capable NP with properties mimicking natural eHNP-A1, challenges remain in reconstituting the full functionality of NPs naturally derived from humans.
|
Authors | Yoshitaka J Sei, Jungho Ahn, Taeyoung Kim, Eunjung Shin, Angel J Santiago-Lopez, Seung Soon Jang, Noo Li Jeon, Young C Jang, YongTae Kim |
Journal | Biomaterials
(Biomaterials)
Vol. 170
Pg. 58-69
(07 2018)
ISSN: 1878-5905 [Electronic] Netherlands |
PMID | 29653287
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Copyright | Copyright © 2018 Elsevier Ltd. All rights reserved. |
Chemical References |
- Anti-Inflammatory Agents
- Apolipoprotein A-I
- Lipoproteins, HDL
- Peptides
- Doxorubicin
|
Topics |
- Animals
- Anti-Inflammatory Agents
(pharmacology)
- Apolipoprotein A-I
(metabolism)
- Biomimetic Materials
(metabolism)
- Doxorubicin
(pharmacology)
- Drug Delivery Systems
- Endothelial Cells
(drug effects, metabolism)
- Female
- HL-60 Cells
- Human Umbilical Vein Endothelial Cells
(drug effects, metabolism)
- Humans
- Lipoproteins, HDL
(metabolism)
- Macrophages
(drug effects, metabolism)
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Nanoparticles
(chemistry, ultrastructure)
- Peptides
(metabolism)
- Time Factors
- Tissue Engineering
- Xenograft Model Antitumor Assays
|